The nNOS-p38MAPK Pathway Is Mediated by NOS1AP during Neuronal Death. by Li, L.L. et al.
Neurobiology of Disease
The nNOS-p38MAPK Pathway Is Mediated by NOS1AP
during Neuronal Death
Li-Li Li,1 Vanessa Ginet,2,3 Xiaonan Liu,1 Olga Vergun,1Minna Tuittila,1,4Marc Mathieu,5 Christophe Bonny,5
Julien Puyal,3 Anita C. Truttmann,2 andMichael J. Courtney1
1Molecular Signalling Laboratory, Department of Neurobiology, A.I. Virtanen Institute, University of Eastern Finland, FI-70211 Kuopio, Finland, 2Division
of Neonatology, Department of Paediatrics and Paediatric Surgery and University Hospital Centre and University of Lausanne, CH-1015 Lausanne,
Switzerland, 3Department of Fundamental Neurosciences, University of Lausanne, CH-1015 Lausanne, Switzerland, 4Turku Centre for Biotechnology,
BioCity, University of Turku and Åbo Akademi University, FI-20521 Turku, Finland, and 5Xigen SA, 1003 Lausanne, Switzerland
Neuronal nitric oxide synthase (nNOS) and p38MAPK are strongly implicated in excitotoxicity, a mechanism common to many neuro-
degenerative conditions, but the intermediary mechanism is unclear. NOS1AP is encoded by a gene recently associated with sudden
cardiac death, diabetes-associated complications, and schizophrenia (Arking et al., 2006; Becker et al., 2008; Brzustowicz, 2008; Lehtinen
et al., 2008). Here we find it interacts with p38MAPK-activating kinase MKK3. Excitotoxic stimulus induces recruitment of NOS1AP to
nNOS in rat cortical neuron culture. Excitotoxic activation of p38MAPK and subsequent neuronal death are reduced by competing with
the nNOS:NOS1AP interaction and by knockdownwith NOS1AP-targeting siRNAs.We designed a cell-permeable peptide that competes
for the unique PDZ domain of nNOS that interacts with NOS1AP. This peptide inhibits NMDA-induced recruitment of NOS1AP to nNOS
and in vivo in rat, doubles surviving tissue in a severemodel of neonatal hypoxia-ischemia, amajor cause of neonatal death and pediatric
disability. The highly unusual sequence specificity of the nNOS:NOS1AP interaction and involvement in excitotoxic signaling may
provide future opportunities for generation of neuroprotectants with high specificity.
Introduction
Excitotoxicity is a multistep mechanism of neurodegeneration
that is common to many acute and chronic diseases of the ner-
vous system for which no therapeutic approaches are available.
Although the mechanisms are not fully understood, initiation of
excitotoxicity is relatively clear. Excess neurotransmitter gluta-
mate leads to calcium entry through NMDA-subtype glutamate
receptors (NRs), which causes neurons to die. However, NRs are
also required for normal brain function and neuronal survival.
Multiple clinical trials have revealed them as therapeutically un-
targetable, and the focus has shifted to downstream events that
mediate neuronal death. Recruitment of neuronal nitric oxide
synthase (nNOS) to activated NRs via PSD-95 contributes to
excitotoxicity (Ferriero et al., 1996; Cao et al., 2005; Ishii et al.,
2006; Zhou et al., 2010). Thus an NR C-terminus mimetic
(“NR2B9C”) that competes with NR for binding the PSD-95–
nNOS complex is neuroprotective (Aarts et al., 2002). Similarly,
competitors of nNOS binding to PSD-95 to nNOS are neuropro-
tective (Cao et al., 2005; Zhou et al., 2010). There is now reason to
be optimistic about the potential therapeutic value of such ap-
proaches as promising results have recently been reported from a
clinical trial using NR2B9C in patients with iatrogenic stroke
(Hill et al., 2012). However, PSD-95 is also critical for neuronal
function. For example PSD-95 knockdown alone greatly disrupts
synaptic AMPA receptor function (Elias et al., 2006; Elias and
Nicoll, 2007), while NO may even have beneficial effects in excito-
toxic conditions (Iadecola, 1997; Atochin et al., 2003). Therefore
protein-interaction targets downstream of nNOSmust be found.
A major obstacle to progress has been the absence of a mech-
anism linking nNOS to downstream excitotoxic events, such as
activation of p38 stress-activated protein kinase (p38MAPK).
This kinase is known to be involved in excitotoxicity but also
contributes to multiple other functions and is itself not a viable
therapeutic target. Here we show that a binding pocket on nNOS,
which is distinct from the PSD-95-binding loop and does not
mediate interaction with PSD-95, is unexpectedly required for
excitotoxic signaling and neuronal death. We find that NMDA
stimulation recruits NOS1AP to nNOS. A synthetic cell-
permeable peptide ligand of the binding pocket inhibits this re-
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cruitment and reduces the activation of p38MAPK, which has
previously been shown to be a nNOS-dependent step contribut-
ing to excitotoxic death (Cao et al., 2005; Soriano et al., 2008).
Supporting a role for NOS1AP in excitotoxicity we find that
siRNA-mediatedNOS1AP knockdown reduces excitotoxic death
and p38MAPK activation. NO can activate multiple MAP3Ks
capable of binding NR-associated molecules such as PSD-95 and
DAB2IP/AIP (Savinainen et al., 2001; Yoshimura et al., 2004;
Zhang et al., 2004; Follstaedt et al., 2008; Hu et al., 2012). Our
results suggest that p38MAPK activation by NR requires
NOS1AP because it is able to recruit and supply p38-activating
MKK3, thereby facilitating the activation of p38MAPK by up-
stream signals. Based on these results, we developed a cell-
permeable peptide competingwith the nNOS–NOS1AP interaction
that is neuroprotective in an in vivo model of neonatal cerebral
hypoxia-ischemia.
Materials andMethods
Materials. Peptides were synthesized as described previously (Yang et al.,
2011) or obtained from GENECUST or GenicBio: “-GESV,” NH2-
YAGQWGESV-COOH; “-GASA,”NH2-YAGQWGASA-COOH; “-ESDV”
or “NR2B9,” NH2-KLSSIESDV-COOH; “-EADA,” NH2-KLSSIEADA-
COOH; “L-TAT,” NH2-GRKKRRQRRR-COOH; “L-TAT-NR2B9C,”
NH2-GRKKRRQRRR-KLSSIESDV-COOH; “L-TAT-GESV,” NH2-GRK-
KRRQRRR-YAGQWGESV-COOH; “L-TAT-GESVamide,” NH2-GRK-
KRRQRRR-YAGQWGESV-CONH2; “L-TAT-GASA,” NH2-GRKKRRQR
RRYAGQWGASA-COOH; “L-TAT-cp4GESV,” NH2-GRKKRRQRRRGE
SVYAGQW-COOH; “L-TAT-revGESV,” NH2-GRKKRRQRRRVSEGWQ
GAY-COOH; “D-TAT-GESV,” NH2-dRdRdRdQdRdRdKdKdRG-
YAGQWGESV-COOH; and “D-TAT-GASA,” NH2-dRdRdRdQdRdRdK
dKdRG-YAGQWGASA-COOH where TAT refers to the sequence from
HIV-TAT protein conferring membrane translocation to cargo; L-TAT re-
fers to TAT sequence composed of L-form amino acids; D-TAT refers to
TATsequence in reverseorder (“retroinverso”) composedofD-formamino
acids; and dR, dW, and dK refer to D-forms of the amino acids arginine,
glutamine, and lysine.
Mouse antibody against GFP(JL-8) was from Clontech; GST(B14),
NOS1(A-11), and MKK3(30) from Santa Cruz Biotechnology;
p38(L53F8 and D13E1) from Cell Signaling Technology; PRK1/PKN1
(49/PRK1) from BD Transduction Laboratories; NeuN(A60/MAB377)
fromMillipore; MAP2 (AP20) from Leinco; GFAP(G-A-5/G3893) from
Sigma; and -actin from Genscript. Rabbit polyclonal antibody against
phospho-(Thr180/Tyr182) p38MAPK was from Cell Signaling Technol-
ogy, CAPON/NOS1AP(R-300) from Santa Cruz Biotechnology, Dan-
syl(A6398) from Invitrogen, and nNOS(Z-RNN3) from Zymed/
Invitrogen. Rabbit anti-MKK3 antiserum and corresponding pre-
immune serum were obtained after/before inoculation with GST-
ratMKK3b, respectively. This antiserum selectively immunoprecipitated
MKK3 not MKK6 (our unpublished observations). Secondary reagents
were from Santa Cruz Biotechnology, Invitrogen, Millipore Biotech,
Jackson ImmunoResearch, and APBiotech.
Fura-5F-AM and Fura-FF-AM were from Invitrogen, DAF-FM-DA
and DEA NONOate from Santa Cruz Biotechnology, LDH/Luciferase
assay kits from Promega, IC87201 from Vitas-M Laboratory, and
BIRB796 from AxonMedchem. Remaining materials were from Sigma,
Apollo Scientific, Alexis, Pierce, APBiotech, Promega, Fermentas,
Finnzymes, New England BioLabs, TamroMedLab, Sarstedt, Tocris Bio-
science, Greiner Bio-One, and Life Technologies.
Cloning, plasmids, and plasmid preparation. Dexras/RasD1 and
MKK3b were amplified from rat cerebellar granule neuron cDNA and
NOS1AP(CAPON) from HEK-293 cDNA as described previously
(Coffey et al., 2002), transferred in-frame after luciferase (from pGL3;
Promega) or VenusYFP to generate pLuc-Dexras, pLuc-MKK3 and
pVenus-NOS1AP. pEGFP-nNOS(1–99) and (1–155) were generated
from previously described pEGFP-nNOS(1–300) (Cao et al., 2005). Re-
placing EGFP with monomeric Cherry produced pCherry-nNOS ver-
sions. The original “empty” Cherry, Venus, and Luciferase vectors served
as controls. pVenus-NOS1AP N terminus and nNOS1–155Y77H/D78E
mutants were generated by PCR-based methods from pVenus-NOS1AP
and pEGFP-nNOS-155, respectively. For recombinant protein expres-
sion in bacteria, coding sequences forMKK3b, nNOS1–300, 1–155wt,
1–155Y77H/D78E mutant, and 1–99 were transferred in-frame to
pGEX-6P3 (APBiotech). pLuc-ASK1 was generated from pcDNA3-HA-
ASK1 (a generous gift from Jim Woodgett, Samuel Lunenfeld Research
Institute, Toronto, Canada) and luciferase vector. The PSD-95-PDZ do-
main and pVenus-C1 plasmids were previously described (Cao et al.,
2005; Semenova et al., 2007).
Recombinant protein preparation. GST-tagged nNOS1–300wt,
nNOS1–99wt, nNOS1–155, and Y77H/D78E; MKK3b; and free
GST were prepared from BL21(DE3) Escherichia coli strain as described
previously (Courtney and Coffey, 1999).
Preparation of immobilized peptides. Synthetic peptides were coupled
via amino groups to affigel10 beads according the manufacturer’s in-
structions (Bio-Rad, 2 mg per 500 l beads). Control empty beads were
prepared by blocking fresh beads without peptide.
Cell culture and transfection. Cerebellar granule neuron cultures, pre-
pared and transfected by calciumphosphate as described previously (Cao
et al., 2005), stimulated with glutamate, were used only for Figure 1,
because these experiments were based on published data in this model
using nNOS1–300 to inhibit glutamate-induced excitotoxicity (Cao
et al., 2005). Cortical neuron cultures, prepared as described previously
(Semenova et al., 2007) and cultured in NeurobasalA/B27 medium (Life
Technologies) and transfected with Lipofectamine 2000 (Life Technolo-
gies), stimulated with NMDA, were used for the remaining figures be-
cause they take upTAT-peptides and are generally considered superior to
evaluate neuroprotection against excitotoxicity. Transfected cells in neu-
ronal cultures were almost entirely neuronal. Cotransfection efficiency is
regularly tested and is almost 100% as reported (Coffey et al., 2002).
Glutamate treatment and pyknosis assay of cerebellar granule neurons.
Excitotoxic stimulation of cerebellar granule neurons [8–10 days in vitro
(DIV)] was as described previously (Cao et al., 2004, 2005) using 30 min
50 M glutamate/10 M glycine (glycine was added so NR activation is
not limited by undefined glycine levels surrounding cells; Courtney et al.,
1990) in magnesium-free Locke’s buffer (Cao et al., 2004), followed by
return to conditioned medium. Cells were fixed with 4% paraformalde-
hyde (PFA) 3 h after stimulation, rinsed twice with PBS, and stained with
2 g/ml Hoechst 33342. EGFP fluorescence identified transfected neu-
rons. Corresponding images of Hoechst fluorescence showed whether
transfected cells had pyknotic/shrunken nuclei (Fig. 1). Images of EGFP
fluorescence were acquired using a 500 nm/20 nm excitation filter, emis-
sion filter 542 nm/27 nm to identify transfected neurons, and corre-
sponding images of Hoechst fluorescence using a 380 nm/10 nm
excitation filter, and emission filter 435 nm LP were acquired. A 10
long-working distance air objective (NA 0.3; Olympus) was used to col-
lect data from replicate samples for quantification and 20 long-
working distance air objective (NA 0.45; Olympus) was used to capture
representative data at higher resolution for Figure 1d.
Imaging with [Ca2]-sensitive and NO-sensitive probes, Fura-5F, Fura-
FF, and DAF-FM. Cerebellar granule neurons were transfected at 7–9
DIV with pmCherry–C1 vector or pmCherry-nNOS(1–99) as indicated
(Fig. 1g–i). Monomeric Cherry was used as fusion protein for expression
constructs to avoid spectral overlap with the DAF-FM channel. DAF-FM
DA is a well accepted fluorescent probe for NO production in neurons
(Zhou et al., 2010) resistant to pH artifacts (Kojima et al., 1999) and ROS
artifacts (we observed no response to 1mMH2O2 or extracellular pH 6.0,
data not shown). Fura-5F and Fura-FF have a lower calcium affinity than
Fura2 and were not saturated even during strong excitotoxic stimulation
(Fura-5F Rmax after ionomycin  2.2  0.05, mean  SEM, n  3
independent samples, whereas R values in experiments did not exceed
0.65 in any case (Fig. 1); Fura-FF Rmax after ionomycin 1.11 0.032,
mean  SEM, n  3 independent samples, whereas R values in experi-
ments did not exceed 0.22; see Fig. 3). Fura-5F was loaded into cerebellar
neurons as AM ester at 5 M in culture medium for 20 min at 37°C.
Where used (Fig. 1) DAF-FM-DA was coloaded by 15 min incubation
with 3 M in Locke’s supplemented with 1 mM MgCl2 and 20 mM KCl.
Cultures were washed twice and imaged in Mg-free Locke’s buffer (334
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nm/ 380 nm excitation and 435 nm/LP emission filters for Fura-5F and
488 nm and 515 nm/LP for DAF-FMusing a BDPathway855 bioimaging
system). Fura-FF was loaded into cultured cortical neurons as AM ester
at 5Mwith 0.005% pluronic inMEMwith or without 1M peptides for
1 h at 37°C as indicated. Cultures were washed twice and imaged in
Mg2-free Locke’s buffer in the presence of peptides (as indicated).
Fura-FF responses were measured with 340 nm/ 380 nm excitation and
515 nm/30 nm emission filters using an Olympus Cell∧R system. Back-
ground corrected excitation ratios (334/380 nm for Fura-5F and 340/380
nm for Fura-FF), which normalizes for differences in dye loading be-
tween cells are shown. DAF-FM is not a ratiometric dye and signals were
normalized to initial values. Responses of all transfected cells in each field
were averaged and means of well averages SEM independent samples
are shown (number of replicates n as indicated in the respective figure
legends).
Immunofluorescent staining of cortical neurons.Cortical neurons (8–10
DIV) were fixed with 4% PFA in PBS, permeabilized 3 min with 1%
Tx100, blocked 60 min with 3% bovine serum albumin-0.2% Tween20-
PSB and incubated overnight with antibodies against nNOS (Z-RNN3,
0.5 g/ml) and MAP2 (1 g/ml) as indicated, in block. Secondary anti-
bodies used were Alexa 488 or 568 anti-rabbit (for nNOS) and Alexa 633
anti-mouse IgG1 (for MAP2, when used). Wide-field images were ob-
tained with a 10 NA 0.4 objective on a BD Pathway 855 imager, and
confocal scans were obtained with a Nikon 40NA 1.3 oil objective on a
Bio-Rad Radiance 2100 confocal scanner using 488 nm argon, 637 nm
red diode, and 405 nm blue diode lasers for nNOS, MAP2, and Hoechst
33342, respectively. Zoom was set at 1.2 and 4.1 for lower and higher
resolution scans.
NMDA treatment, phospho-p38 immunoblotting, and cell death assay
for cortical neurons. Excitotoxic stimulation of cortical neurons (8 DIV)
was performed as follows. Neurobasal/B27 medium contains neuropro-
tectants that interfere with excitotoxicity assays and was replaced with
MEM supplemented with glutamine, penicillin/streptomycin  pep-
tides, or inhibitors BIRB796/IC87201 1 h before NMDA as indicated.
p38MAPK activation was determined by immunoblotting of cleared
neuron lysates in Laemmli buffer after 10 min NMDA treatment.
For cell death assay, stimulation with NMDA (0–50 M) was termi-
nated at 1 h by 1 MMK801 (Tocris Bioscience). Cell death was assessed
24 h after NMDA addition. LDH release was measured by cytotoxicity
assay (Promega kit). Control experiments indicated that MK801 expo-
sure alonewas not toxic within the experimental time frame (our unpub-
lished observations). After sampling for LDH assay, 1 g/ml Hoechst
33342 and 2g/ml propidium iodide (PI) were added to cells 15–30min
followed by imaging (BD Pathway855 bioimaging system, 10 objective
and appropriate excitation, emission, and dichroic filters). The number
of PI-positive cells imaged from each well was determined with the aid of
AttoVision1.7 software (BD Biosciences). The number of independent
replicate wells n is indicated in all figures. Neuronal death data shown
were obtained from neurons from 2–5 independent cell preparations in
each case.
siRNA knockdown in cortical neurons. siRNAs targeting NOS1AP or
MKK3 and control siRNAs were obtained from Dharmacon/Thermo-
Fisher (“siGENOMEON-TARGETplus”) andMicrosynth. All sequences
are available on request. siRNA were cotransfected with carrier DNA
(pVenus-C1) at 5 DIV with Lipofectamine 2000 (Invitrogen) according
to themanufacturer’s instructions. Neuronswere stimulated at 8DIV for
p38 activation and cell death experiments. Knockdown of NOS1AP and
MKK3 compared with controls was evaluated by immunoblotting.
Coimmunoprecipitation from cortical neurons and cortex lysate followed
by immunoblotting. Cortical neurons or cerebral cortical tissue from
postnatal day 7 (P7) rats was homogenized with low-salt buffer (LSB;
Cao et al., 2005) supplemented with protease inhibitors and nonionic
detergent (0.5% Igepal), and precleared at 20,000 g/4°C for 10 min.
nNOS antibody (A-11, 2.5 g/ml) or rabbit antiserum raised against rat
MKK3b (7.5 l/ml) was added to each lysate (controls used were pre-
immune serum from the same rabbit for anti-MKK3, and protein-A
beads alone for the monoclonal anti-nNOS). Lysates were rotated for 2
h/4°C, 5 l of protein-A beads added, and rotation continued 1 h. Beads
were washed three times with the same buffer, and drained beads were
boiled in Laemmli sample buffer for immunoblotting, performed as de-
scribed previously (Coffey et al., 2002).WhenNOS inhibitors were used,
cortical neurons were pretreated without or with inhibitors,
7-nitroarginine (7-NI; 3 M), N-propyl-L-arginine (N-pArg; 1 M),
or N-nitro-L-argininemethyl ester (L-NAME; 500M) in arginine-free
medium for 30 min at 37°C. After 10 min treatment with or without
50 M NMDA, neurons were lysed and coimmunoprecipitation per-
formed as above. Note that while N-pArg is reportedly selective for
nNOS, L-NAME and 7-NI inhibit all NOS isoforms (Alderton et al.,
2001; but 7-NI is preferentially taken up by neurons; Cao et al., 2005).
Protein-peptide ligand interaction assay by pulldown of GST-fusion pro-
teins. Affigel10 bead-immobilized peptides were used to pull down solu-
ble recombinant GST-fusion proteins to evaluate the formation of stable
complexes. GST was used as a negative control to ensure the buffer con-
ditions used did not result in nonspecific interactions. Immobilized pep-
tide beads (5 l bed) in LSB/protease inhibitors and 0.5% Igepal
detergent as above were rotated with 3 g of soluble GST-fusions for 2
h/4°C, before washing and analysis by immunoblotting as above.
Protein–protein interaction assays with luciferase-fusion proteins. Pre-
cleared HEK-293T lysates transfected with pLuc-ASK1 or NOS1AP
(pLuc-C1 as control) in LSB/protease inhibitors and 0.5% Igepal deter-
gent were rotatedwith 2g of bead-immobilizedGST orGST-MKK3 for
1 h/4°C. Beads were washed three times in LSB/protease inhibitors and
0.5% Igepal detergent, and drained beads resuspended in passive lysis
buffer (Promega). Luciferase in bead and supernatant fractions were
measured and precipitated activity was normalized to total levels for each
sample.
Precleared HEK-293T lysates cotransfected with pVenus-NOS1AP N
terminus and pLuc-Dexras or pLuc-MKK3 (pVenus-C1 and pLuc-C1 as
controls) in LSB/protease inhibitors and 0.5% Igepal detergent were co-
immunoprecipitated by rotation 1 h/4°C with 5 l of “GFP-Binding
Protein” beads coupled to a single-chain camelid antibody-based protein
(“GFP-Trap”; Chromotek). Beads were washed three times in the LSB/
protease inhibitors and 0.5% Igepal detergent; drained beads were resus-
pended and pulldown determined by luciferase assay as above.
Assay for competitive inhibition of protein–protein interactions by pep-
tides. Precleared HEK-293T lysates transfected with pEGFP-PSD-95-
PDZ2 or pEGFP-C1 as control in LSB/protease inhibitors and 0.5%
Igepal detergent were rotated with 2 g of bead-immobilized GST or
GST-nNOS 1–155 with or without 1 M L-TAT-NR2B9C or 1 M
L-TAT-GESV for 1 h at 4°C. Beads were washed three times in LSB/
protease inhibitors and 0.5% Igepal detergent, and drained beads boiled
in Laemmli sample buffer for SDS-PAGE followedCoomassie staining to
visualize GST-fusion proteins and semidry transfer and immunoblotting
to visualize GFP-fusion proteins.
Neonatal cerebral hypoxia-ischemia model. All experiments were per-
formed in accordance with the Swiss Laws for the protection of animals
and approved by theVaudCantonal VeterinaryOffice. Neonatal cerebral
hypoxia-ischemia was induced in P7male rats (16–19 g SpragueDawley;
Janvier) according to the Rice–Vannucci model (Rice et al., 1981) as
described previously (Ginet et al., 2009). Right common carotid artery
was double ligated and cut in 3% isoflurane-anesthetized rat pups. After
2 h recovery with the dam, pups were exposed 2 h to humidified 8%O2-
92%N2. Ambient temperature during hypoxia in the chamber wasmain-
tained at 35.5°C. Peptides (100 ng) in 4 l of 0.9% NaCl, p38 inhibitor
SB203580 (10 nmol; Calbiochem) in 5 l of 20% dimethylsulfoxide
(DMSO) carrier or carrier alone were injected intracerebroventricularly
to the right hemisphere just after carotid occlusion. Pups were returned
to the dam for 24 h or 7 d after hypoxia-ischemia. Dissection and immu-
noblot analysis were as described previously (Ginet et al., 2009). For
immunohistochemistry and brain lesion volume analysis, rat pups
deeply anesthetized by intraperitoneal injection of 150 mg/kg sodium-
pentobarbital were transcardially perfused with 4% PFA in 0.1mol/L
PBS, pH 7.4. Cryostat coronal serial sections (50 m) were cut and
stained with cresyl violet for lesion analysis. Contralateral and ipsilateral
surviving brain areas were measured every 500 m using Neurolucida
software (MicroBrightField). Unlesioned volume was calculated with
Neuroexplorer (MicroBrightField). Percentage of surviving tissue was
calculated using the formula (ipsilateral surviving volume/contralateral
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volume 100%). Thewhole tissue lesion size in control (D-TAT-GASA-
treated) animals was very similar to our other negative controls in this
model (Ginet et al., 2009). The lower lesion size in DMSO-treated con-
trols, compared with animals receiving different control peptides here
and previously (Ginet et al., 2009), may result from the reported neuro-
protective effect of DMSO alone (Greiner et al., 2000) in rat neonatal
hypoxia-ischemia and other models (Greiner et al., 2000; Zhu et al.,
2003). For immunohistochemistry, slices stained with Alexa Fluor 488
donkey–anti-rabbit (A21206; Invitrogen) and Alexa Fluor 594 donkey—
anti-mouse (A21203; Invitrogen) were imaged with a Zeiss LSM 710
confocal laser-scanningmicroscope (Carl Zeiss) with Zeiss plan neofluar
10/0.30 NA objective. For double labeling, immunoreactive signals
were sequentially visualized in the same section with different filters.
Statistical analysis. GraphPad-Prism was used for statistical analysis.
Data were analyzed by ANOVA (two-way for cell death and one-way for
other data) and post hoc Bonferroni test (except for in vivo experiments).
Surviving tissue, normalized to contralateral tissue, were verified to be
normally distributed and analyzed statistically by Welch’s ANOVA for
unequal variance (two-tailed) followed by a post hoc Tukey–Kramer test.
Resulting p values are shown in figure legends, p 0.05 being considered
significant.
Results
Inhibition of excitotoxicity by class III PDZ domain
TheN terminus of nNOS (amino acids 1–300; Fig. 1a) consists of
a core PDZ domain (nNOS amino acids 1–99) with unusual
“class III” peptide binding selectivity distinct from typical PDZ
domains such as PSD-95-PDZ2 (Stricker et al., 1997, Schepens et
al., 1997) (Fig. 1b), followed by a -finger sequence that binds
directly to PSD-95 (Tochio et al., 1999, Christopherson et al.,
1999). Thus neuronal expression of the nNOS1–300 fragment,
that contains the -finger, reduces glutamate-evoked neuronal
death (Cao et al., 2005; Fig. 1c–f), but we were surprised to find a
similar protection even using a fragment of nNOS, which lacks
the -finger and consists only of the core PDZ (nNOS 1–99, Fig.
1c–f). The unique sequence selectivity of this domain (Fig. 1b)
does not have a known role in excitotoxic signaling. Although
expression of free PSD-95-PDZ2 is neuroprotective (Aarts et al.,
2002; Cao et al., 2005), nNOS1–99 does not merely mimic free
PSD-95-PDZ2 domain, because it completely fails to bind beads
coated with a PSD-95-PDZ2 ligand derived from the NR2B NR
subunit (“ESDV”; Fig. 1b). This suggested that the highly unusual
preference of the nNOS-PDZ binding pocket (Fig. 1b) could be-
come a new target for neuroprotectants, perhaps amore selective
alternative to the described-finger:PSD-95-PDZ2 and themore
generic PSD-95-NR type PDZ class I interactions (Aarts et al.,
2002; Cao et al., 2005; Zhou et al., 2010).
Neuroprotection by class III PDZ domain is not mediated by
reduced calcium/NO responses
One possible explanation for the neuroprotection might be that
nNOS1–99 expression reduces glutamate-induced calcium re-
sponses or subsequent NO generation. This is a critical point to
clarify because calcium is known not to be a useful therapeutic
target in excitotoxic diseases. However, nNOS1–99 competes
with PDZ class III interactions which, unlike the interactions
within theNR–PSD-95–nNOS complex (Aarts et al., 2002; Cao et
al., 2005; Ishii et al., 2006; Zhou et al., 2010), are not known to be
required forNO synthesis. Using established probes for freeCa2
and NO (Kojima et al., 1999; Fura-5F and DAF-FM; Cao et al.,
2005) under conditions in which signals were not saturated we
observed no evidence of reduced glutamate responses by expres-
sion of nNOS1–99 (Fig. 1g,h), even with fast imaging to accu-
rately capture the initial calcium transient (Fig. 1i).
The extended PDZ domain of nNOS forms a ternary complex
We considered whether nNOS1–99 expression might compete
with recruitment of a previously unknown excitotoxic effector of
the endogenous PSD-95–nNOS signaling complex, via the
nNOS-PDZ peptide binding pocket (Fig. 2a). For this to occur
(1) cells undergoing excitotoxic death should express nNOS and
(2) regions within endogenous nNOS should have the capacity to
simultaneously interact with PSD-95 and peptide ligand. It is
widely accepted that nNOS is highly expressed in only 1% of
cortical neurons (Bredt et al., 1991; Samdani et al., 1997). Unless
other neurons also express some level of nNOS, it appears un-
likely that the recruitment of signaling molecules by nNOS (Fig.
2a) could mediate excitotoxic signaling downstream of NO. It
has therefore been proposed that NO diffusing from cells ex-
pressing high levels of nNOS cause the death of neighboring cells
(Samdani et al., 1997). However, there are reports suggesting that
low-level nNOS expression is widespread (Wendland et al., 1994;
Burette et al., 2002; Langnaese et al., 2007). We stained cortical
cultures with antibody Z-RNN3 raised against the N terminus of
nNOS, which has been successfully used for a range of staining
procedures (Valtschanoff and Weinberg, 2001; Burette et al.,
2002). We find that a small minority of cells exhibit very bright
diffuse staining (Fig. 2bi); nevertheless there is widespread punc-
tate staining of other cells (Fig. 2bii, iii, v–vi) even though the
levels were a few fold lower than the brightest cells. As the impact
of nNOS on signaling depends entirely on the proteins with
which it interacts (Aarts et al., 2002; Cao et al., 2005; Ishii et al.,
2006; Soriano et al., 2008), it is possible the impact of differences
in bulk nNOS levels between cells may have been overestimated.
Next we considered whether regions within endogenous
nNOS have the capacity to simultaneously interact with PSD-95
and peptide ligand. The nNOS-PDZ--finger tandem domain
has a well established capacity to bind to both peptide ligands and
PSD-95 (Tochio et al., 1999; Christopherson et al., 1999), and
structural data clearly shows the interacting surfaces for each to
be structurally distinct and on opposite sides of the molecule
(Christopherson et al., 1999; Hillier et al., 1999; Fig. 2c, nNOS-
core PDZ shown in pink in both PDB structures,-finger in gray,
and peptide ligand in lilac). This suggests the tandem domain
might be able to form a ternary complex via these interactions.
However, this has remained controversial, with one report sug-
gesting that ligand binding releases PSD-95 from nNOS (Jaffrey
et al., 1998), a second suggesting that nNOS is able to assemble a
ternary complex with PSD-95 and nNOS ligand (Christopherson
et al., 1999), while structural studies of the nNOS N terminus
concluded that peptide ligands are unlikely to compete with
PSD-95 binding to the -finger (Tochio et al., 1999). In light of
this conflict, we investigated whether the N terminus of nNOS
(i.e., containing both core PDZ and -finger sequence) has the
capacity to bind both PDZ peptide ligand and -finger ligand
simultaneously in a manner dependent on both -finger region
and ligand-binding pocket.We expressed wild-type andmutated
nNOS fragments (Fig. 2d, top) and, using the fragments captured
on beads for pulldown assays with GFP-tagged PSD-95-PDZ2,
we first confirmed that nNOS binding to PSD-95-PDZ2 depends
on the -finger region absent in nNOS1–99 (Fig. 2d, PDZ pull-
down shown in bottom film) as expected (Christopherson et al.,
1999), i.e., PSD-95-PDZ2 does not bind the core nNOS-PDZ
domain (nNOS1–99) thatwe have shown is neuroprotective (Fig.
1). We find that binding to PSD-95 via the -finger region is not
affected by mutation of the binding pocket (76YH and
77DE). Subsequently we immobilized the specific nNOS
peptide ligand from Figure 1b (“GESV”; Schepens et al., 1997).
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Figure 1. The core PDZ domain of nNOS unexpectedly inhibits excitotoxic deathwithout effect on calciumor NO responses.a, Representation of theN terminus of nNOS (amino acids 1–300) that
has been shown to be neuroprotective (Cao et al., 2005). The nNOS-PDZ domain is comprised of a core PDZ domain (amino acids 1–99) of class III specificity followed by the-finger (amino acids
100—130). The-finger recruits nNOS to the second PDZ domain of PSD-95, leaving the peptide binding pocket of the nNOS-PDZ exposed (Fig. 2; Christopherson et al., 1999; Tochio et al., 1999).
b, The core PDZ domain of nNOS sequence 1–99, produced as a GST-fusion protein (shown on the Coomassie gel on the left), selectively binds bead-immobilized class III PDZ ligand motif (-GESV,
named after the 4 C-terminal amino acids of the nonamer) as shown in the blot on the right, but not to the 9 C-terminal amino acids of NR2B (-ESDV), nor to control peptides in which C and C-2
residues are replaced with alanine (-GASA, -EADA) or peptide-free beads (“Beads”). Correspondingly PSD-95-PDZ2, a class I domain, binds NR2B C terminus (-ESDV) but not the other peptides or
controls (n 3 independent samples for each condition). c, Schematic representation of GFP-fused nNOS fragments used in excitotoxicity assays. d–f, Expression of N-terminal fragments of nNOS
containing amino acids 1–300, 1—155, or even only 1–99 (the core PDZ domain) fused to GFP all significantly reduced glutamate-induced pyknosis, an indicator of excitotoxic death of cerebellar
neurons (Cao et al., 2004), compared with GFP control (e, n 6 wells/condition). Pyknosis of the untransfected cells was not affected by the constructs (f ). Representative images (94mwidth)
of nuclei and GFP fluorescence are shown in d. Cerebellar granule neuron cultures were used in these experiments as they were based in published data demonstrating neuroprotection by
nNOS1–300 in this neuronal type. g, h, Neurons were loaded with indicators for calcium (Fura-5F, Rmax 2.2) and NO (DAF-FM; Kojima et al., 1999) and imaged for 15 min after excitotoxic
stimulation (50M glutamate/10M glycine) as used in d. Top traces from transfected cells and bottom traces from untransfected cells in the same fields. No reduction in response was caused by
expression of nNOS1–99. Signals from all cells imaged in awell were averaged at each time point andmeans SEM shown are determined from these well averages; (Figure legend continues.)
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This peptide failed to bind PSD-95-PDZ2 whether nNOS1–99
was present or not (Fig. 2e, bottom film, pulldown lanes 1–4),
although it bound to nNOS1–99 (Fig. 2e, top film, lane 4) con-
sistent with Figure 1b. Finally, in the presence of wild-type nNOS
PDZ--finger tandemdomain, the peptide acquired the ability to
pulldown PSD-95-PDZ2 (Fig. 2e, pulldown lane 6, both films).
This is consistent with the formation of a ternary complex of
bead-bound GESV peptide and PSD-95-PDZ2 bridged by nNOS
tandem domain. In support of this, mutation of the nNOS pep-
tide binding pocket (“YD/HE”; Christopherson et al., 1999) si-
multaneously abrogates both binding of nNOS to peptide and the
facilitated binding to PSD-95-PDZ2 (Fig. 2e, pulldown lane 8,
both films).
Cell-permeable peptide ligand of nNOS-PDZ protects against
excitotoxic death
The inhibition of excitotoxic neuronal death by nNOS1–99 (Fig.
1) may be a consequence of nNOS-mediated recruitment of an
effector of neuronal death downstream or independent of calcium/
NO pathways (“endogenous ligand”; Fig. 2a). This presents the
intriguing possibility that a small cell-permeable ligand of the
nNOS-PDZ domainmight itself be neuroprotective while having
the advantage of being a small-molecule compound, unlike the
nNOS1–99 expression strategy used in Figure 1. Short peptide
sequences can be delivered to intracellular targets by fusing them
to a basic sequence derived from HIV-TAT peptide. Thus
D-JNKI, which prevents c-Jun N-terminal kinase (JNK) from
interacting with substrates, enters cortical neurons in culture and
in vivo (Borsello et al., 2003). The nine C-terminal amino acids of
NR subunit 2B, termed NR2B9C, can similarly be delivered to
inhibit interaction of NRs with PSD-95 (Aarts et al., 2002). The
corresponding peptides are in clinical trials for cerebral ischemia,
as they are both able to provide neuroprotection of cortical neu-
rons, albeit by targeting the major hubs of neuronal function,
JNK, and PSD-95 (Coffey et al., 2002; Kim and Sheng, 2004;
Bjo¨rkblom et al., 2005; Westerlund et al., 2008, 2011; Yang et al.,
2011). In contrast, here we appear to have an opportunity to use
a short peptide ligand for a unique PDZ domain that is not
known as a major cellular regulator, unlike JNK and PSD-95.
To test this hypothesis, we synthesized a form of the nonamer
GESV ligand used in Figures 1b and 2e fused at the N terminus to
TAT, using L-form amino acids. First, we evaluated whether
added peptide is indeed able to compete with and reduce protein
interactions with the nNOS-PDZ domain in intact cells. We
treated cortical neuron cultures with the resulting synthetic pep-
tide L-TAT-GESV in the presence and absence of 50 M NMDA
and immunoprecipitated endogenous nNOS (Fig. 3a). Copre-
cipitation of the best characterized nNOS-PDZ ligand, NOS1AP
(also known as CAPON; Jaffrey et al., 1998), was evaluated by
immunoblotting. This revealed that NMDA unexpectedly en-
hanced interaction of NOS1AP with nNOS in neurons. L-TAT-
GESV inhibited the interaction (Fig. 3a,b). Subsequently we
treated cortical cultures without peptide, with L-TAT sequence
alone, L-TAT-NR2B9C as a well established positive control neu-
roprotectant that disrupts PSD-95 function (Aarts et al., 2002;
Soriano et al., 2008), or L-TAT-GESV followed by increasing
concentrations of NMDA. This revealed that L-TAT-GESV
greatly reduced cell death after NMDA, measured by either PI
staining to reveal somatic damage and access of the nucleus to the
membrane-impermeant dye (Fig. 3c,d), or the more sensitive
LDH release assay to reveal leakage of cytoplasm from either
somatic or neurite compartments (Fig. 3e). The preceding exper-
iments with nNOS1–99 suggest we have identified a previously
unrecognized site for design of neuroprotectants. The novel neu-
roprotective peptide we designed was based on a selective ligand
for the nNOS-PDZ domain pocket. Nevertheless, it is possible
that this new reagent does not have the expected specificity. PSD-
95-PDZ2 is believed to be the target of TAT-NR2B9C (Aarts et al.,
2002; Cui et al., 2007). Any effect on this domain could lead to
neuroprotection via inhibition upstream of nNOS function,
rather than downstream aswe have concluded. The PSD-95-PDZ
ligand L-TAT-NR2B9C (1 M) clearly reduces the interaction of
PSD-95-PDZ2 with -finger containing nNOS fragment (40 
6%) as expected, but 1 M L-TAT-GESV has no effect (103 
5%). The inhibitory effect of L-TAT-NR2B9C in our experiments
is half that obtained by Cui et al. (2007) who used nNOS1–120
and is instead similar to the reported inhibition of PSD-95-PDZ2
interaction with NR2A/C (Cui et al., 2007). This is likely to be
explained by the presence of nNOS residue Arg121 in our exper-
iments, which mediates salt-bridge stabilization of the -finger
(Tochio et al., 2000; Harris et al., 2001) and which is absent in the
nNOS1–120 construct previously used to characterize TAT-
NR2B9C (Cui et al., 2007).
We also performed the excitotoxicity neuroprotection assay
using PI (Fig. 3g,h) and LDH (data not shown) to evaluate a panel
of control peptides including scrambled peptides and a amidated
form of TAT-GESV, which is the minimal change–replacement
of a single oxygen atomwith a with nitrogen–that abolishes bind-
ing of peptide ligands with PDZ domains (Harris et al., 2001).
These experiments showed that only L-TAT-GESV and L-TAT-
NR2B9C were neuroprotective (Fig. 3g) and that removing the
TAT sequence prevents neuroprotection in both cases (Fig. 3h).
In addition we found that basal and NMDA-evoked calcium lev-
els in cortical neurons were not affected by either L-TAT-GESV
peptide or by any control peptide tested (Fig. 3i).
TAT-GESV selectively inhibits excitotoxic
p38MAPK activation
To address the possible mechanism by which TAT-GESV pro-
vides neuroprotection, we askedwhether the peptidemight affect
p38MAPK activation. We and others have reported that activa-
tion of p38MAPK mediates the contribution of nNOS to excito-
toxicity in cerebellar and cortical neurons (Kawasaki et al., 1997;
Cao et al., 2004, 2005; Soriano et al., 2008). Under the conditions
of Figure 3, inwhich L-TAT-GESVwas neuroprotective,NMDA-
induced cortical neuron excitotoxicity was reduced by a pan-
p38MAPK inhibitor BIRB796 (Kuma et al., 2005; Fig. 4a). A
similar neuroprotection was obtained using a recently described
small-molecule mimetic of nNOS1–300 that competes against
interaction of nNOS--finger with PSD-95, IC87201 (Florio et
al., 2009; Fig. 4b). Furthermore, IC87201 also reduces excitotoxic
4
(Figure legend continued.) n 8, 4, 6, and 6 wells for Vector/Control, nNOS1–99/Control,
Vector/Glutamate, and nNOS1–99/Glutamate, respectively. i, Rapid imaging reveals no signif-
icant effect of the core PDZ domain of nNOS (amino acids 1–99) on the glutamate-induced free
calcium response. The initial transient of the calcium response to excitotoxic stimulation (added
at time0), 50Mglutamate/10Mglycine asused ind,wasmeasuredbypreloading cerebellar
granule neurons with only Fura-5F and rapidly measuring background-corrected 334/380 nm
ratios. the top shows traces from transfected cells and the bottom shows traces from untrans-
fected cells in the same fields. The Fura-5F ratio response was not significantly reduced by the
expression of nNOS1–99 (n 7 and 8 independent wells for Vector and nNOS1–99, respec-
tively, calculatedas forgandh). Calciumsignalswerenot saturating in thesedataor inhasRmax
(after ionomycin treatment) 2.2  0.05 (mean SEM, n  3 independent samples).
Significant differences from corresponding samples as shown, at *p 0.05, **p 0.01, and
***p 0.001, respectively, by post hoc Bonferroni test subsequent to ANOVA test.
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activation of p38MAPK (Fig. 4c,d), in agreement with our previ-
ous results using nNOS1–300 (Cao et al., 2005). These data are
consistent with a contribution of both -finger/PDZ-type inter-
actions and p38MAPK to the mechanism of excitotoxic death in
the present model. Evaluating the effect of the peptides on re-
sponses to 50 M NMDA revealed that TAT-GESV, like the
upstream-acting TAT-NR2B9C (Soriano et al., 2008), inhibited
NMDA-evoked p38MAPK activation (Fig. 4e,f) whereas TAT
alone did not.
Thus TAT-GESV binds nNOS; disrupts interaction of nNOS
with the endogenous ligand NOS1AP; and reduces downstream
excitotoxic events, p38MAPK activation, and cell death. This
suggests that the peptide either uncouples NMDA-induced NO
signals from downstream events ormerely directly and nonselec-
tively inhibits the responsiveness of the p38MAPK pathway to
activating signals such as NO. To distinguish between these pos-
sibilities, we induced neuronal p38MAPK activity directly with
the NO donor, which bypasses the need for the NR–PSD-95–
Figure 2. The extended PDZ domain of nNOS forms a ternary complex with peptide ligand and a PSD-95 domain. a, Previous data have established the role of the NR–PSD-95–nNOS ternary
complex in excitotoxic activationof p38MAPKandneuronal death (Aarts et al., 2002; Cao et al., 2005). This scheme shows the complex results fromdockingof theNRC terminuswith onePDZdomain
of the multidomain scaffold protein PSD-95 and docking of the nNOS-PDZ domain -finger (indicated by the dotted line) with PSD-95-PDZ2. Calcium influx through the NR activates the
appropriately localized nNOS catalytic domain (Ishii et al., 2006). Expression of free nNOS(1–99) core PDZ domain is presumed to act via sequestration of endogenous class III PDZ ligands and
therefore competes at the PDZ binding pocket of endogenous nNOS as shown, leading to neuroprotection (Fig. 1). b, Immunofluorescent staining of cortical neuron cultures with nNOS antibody
Z-RNN3 (Valtschanoff andWeinberg, 2001) reveals a few intensely stained cells (i) andwidespread dimmer staining visible after contrast adjustment (ii). Scale bar, 50m,wide-fieldmicrographs
are shown. Distribution ofwidespreaddim stainingwith nNOS antibody (green; counterstainedwith anti-MAP2, shown in red) is seenby laser confocal-scanningmicroscopy (iii),while the negative
control, a parallel samplepreparedwithout primary antibodies and scannedunder identical laser power, detector, andother settings, showsno signal (iv). Scale bar, 10m.Theblue arrow indicates
one of several thin processes from an intensely stained cell crossing this field. The region in the blue box was scanned at higher resolution at different focal planes in v–vii, showing clear and
predominantly cytoplasmic staining with the nNOS-antibody (green; DNA counterstained with Hoechst 33342 shown in blue). Scale bar, 10m. The blue arrow indicates one of the thin bright
processes seen in the box in iii. c, Representation of solved extended PDZ domain structures (PDB 1B8Q; Tochio et al., 1999 and 1QAV; Hillier et al., 1999) showing the binding pocket of nNOS that
binds peptide ligands (lilac, shown in 1B8Q) on the left is on the opposite side of the extended PDZ domain to the-finger (shown in gray) that binds PSD-95-like PDZ domains (in green, shown on
the right).d, Bead-immobilizedGST fusions of nNOSPDZdomainwith andwithoutmutation (“dm”) of thebindingpocket anddeletionof the-finger are shown schematically above corresponding
laneswhere they are shownby Coomassie (top). Thesewere used in pulldownassaywith cell lysate expressingGFP-fusedPSD-95-PDZ2 (bottom), showingbinding of the PSD-95domain dependent
on the-finger as expected but independent of the PDZ pocket double mutation, dm or YD/HE (n 3). e, Soluble GST-fused nNOS fragments corresponding to those in c together with GFP-fused
PSD-95-PDZ2were used in pulldownassayswith a bead-immobilized ligand for nNOS-PDZ as in Figure 1b, showing the ligand can coprecipitate PSD-95-PDZ2 only ifwild-type nNOS-PDZpocket and
-finger are both present (n 3).
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Figure 3. TAT-GESV inhibits interaction of nNOS with endogenous nNOS-PDZ ligand and protects cortical neurons from excitotoxic cell death. a, Cortical neurons were treated for 1 h with or
without 1M L-TAT-fused nNOS-PDZ ligand (TAT-GESV) followed by 10 min with or without 50M NMDA as indicated. Cells were lysed and immunoprecipitated with anti-nNOS followed by
immobilized protein A. Coprecipitated NOS1AP and precipitated nNOSwere detected by immunoblotting in all samples, with corresponding total lysate samples (“Input”) shown below. Represen-
tativeblots (n4) are shown, indicating thepeptide reducesNOS1APcoprecipitationafterNMDA.b, CoprecipitatedNOS1AP levels fromquantitated filmsof replicates as inaare shown,normalized
to precipitated nNOS. A significant difference between control-NMDA and L-TAT-GESV-NMDA-treated samples is observed. c– e, Cortical neurons were treated 1 h as indicated with or without
cell-permeant L-TAT-GESV peptide, TAT alone lacking the GESV sequence as a negative control, or L-TAT-NR2B9C as a positive control (peptides 1M in all cases), and excitotoxicity induced by 1 h
stimulation with 25 or 50M NMDA as described (see Materials andMethods). After 24 h, culture media were sampled to assay LDH as an indicator of cell death, and cultures were incubated with
Hoechst 33342,which stains all nuclei, and PIwhich stains nuclei of cells that have lost plasmamembrane integrity. c, Representative images (75mwidth) of fluorescent dye staining are shown, indicating
fewer PI-positive cells after GESV treatment. d, e, The percentage of PI-positive cells is shown (n 12; d); the LDH release (% of total) is shown (n  12; e). f, (Figure legend continues.)
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nNOS complex (Cao et al., 2005). The presence of L-TAT-GESV
in this case did not reduce p38MAPK activation (Fig. 4g,h). The
PSD-95-nNOS interaction inhibitor IC87201 did not reduce NO
donor-induced p38MAPK activation either (Fig. 4i,j). Thus
L-TAT-GESV selectively inhibits NMDA-evoked activation of
p38MAPK.
NOS1AP interacts with p38MAPK-activating kinase and
siRNA-mediated knockdown reduces excitotoxic signaling
Our data suggest that the nNOS peptide-binding pocket recruits
machinery specifically required for activating p38MAPK and cell
death in response to NMDA. It is conceivable that this could be
an appealing selective target for drug development. However,
these data have not shed light on themechanism. Intrigued by the
NMDA-induced recruitment to nNOS we observed when using
NOS1AP as amarker of nNOS-PDZpocket function (Fig. 3a), we
investigated whether NOS1AP might play an active role in exci-
totoxic signaling. We obtained two independent siRNAs able to
knock down NOS1AP levels to 50% in neurons (Fig. 5a). We
found these siRNAs also reduce NMDA-induced cell death (Fig.
5b–d), though not as effectively as the peptide, perhaps because
knockdown methods are typically not 100% efficient. Both
NOS1AP-targeting siRNAs also reduced p38MAPK activity after
NMDA (Fig. 5e–g for siRNA #1; h–j for siRNA #2), consistent
with an active role for NOS1AP in NMDA-evoked activation of
p38MAPK and ensuing neuronal death.
To understand the possible contribution of NOS1AP to
p38MAPK activation we investigated candidate interacting pro-
teins, and found that the p38MAPK activatorMKK3 coimmuno-
precipitates endogenous NOS1AP from brain considerably more
efficiently than the known MKK3-interacting protein PKN
(Takahashi et al., 2003; Fig. 6a). Recombinant protein interaction
assays indicate that NOS1AP interacts with MKK3 and the
known NOS1AP-interacting protein DexRas (Fang et al., 2000)
to similar extents (Fig. 6b), while MKK3 interacts with NOS1AP
and another MKK3-interacting protein ASK1 to similar extents
(Fig. 6c). Due to limitations with the antibodies we have testedwe
have not been able to investigate whether the two proteins inter-
act with one another in intact cells. However, we can conclude
that NOS1AP can interact with the p38MAPK activator MKK3
and that pre-existing NOS1AP–MKK3 complexes can be isolated
from brain tissue.
NOS1AP knockdown reduces excitotoxic activation of
p38MAPK and ensuing death, and a peptide that competes with
4
(Figure legend continued.) InteractionbetweenGST-fusednNOS1–155, containingbothPDZ
binding pocket and-finger ligand, and GFP-fused PSD-95 PDZ2 is reduced by L-TAT-NR2B9C
but not L-TAT-GESV (bottom). GST-fused nNOS 1–155 and free GST used in the experiment are
shown by Coomassie staining (top). Representative data are shown (n  3). g, h, Cortical
neurons were treated 1 h as indicated with or without negative controls L-TAT, L-TAT GASA,
L-TAT-revGESV (nonamer sequence reversed), L-TAT-cp4GESV (cyclin permutation of nonamer
sequence at position 4), the C terminally amidated L-TAT-GESVamide, or the neuroprotective
L-TAT-NR2B9C or L-TAT-GESV peptides (g), or with NR2B9C (without TAT sequence), GESV
(without TAT sequence), L-TAT-NR2B9C, and L-TAT-GESV peptides (h), followed by excitotoxic
treatment as in c– e. All peptides were used at 1M, using L-form amino acids and sequences
are shown (seeMaterials andMethods). After 24 h, culturemediawere sampled to assay LDHas
an indicator of cell death (data not shown), and cultures were incubated with Hoechst 33342,
which stains all nuclei, and PI which stains nuclei of cells that have lost plasma membrane
integrity. The percentage of PI-positive cells is shown here (n 20 for g and n 8 for h). i,
Cortical neurons were untreated (CONTROL) or treated 1 h with 1 M L-TAT, L-TAT-GASA,
L-TAT-cp4GESV, L-TAT-GESV, andD-TAT-GESVpeptides (n8, 4, 4, 4, 4, and3wells/condition,
respectively) and loaded with indicator for calcium (Fura-FF, Rmax 1.11 0.03, n 3 wells).
Background-corrected 340/380 nm excitation ratios of Fura emissions (which normalizes for
differences indye loadingbetween cells) before and30 s afterNMDAare shown. Signals fromall
cells imaged in awellwere averaged andmeans SEM shown are determined from thesewell
averages. No change fromcontrol level is caused by any peptide tested. *p 0.05, **p 0.01,
and ***p 0.001, respectively, by Bonferroni post hoc test after ANOVA in all cases.
Figure 4. Excitotoxicity is reduced by inhibitors of p38 and nNOS-PSD-95 interaction; TAT-GESV inhibits p38 activation. a, Cortical neuron cultures were pretreated 1 h with pan-p38 inhibitor
BIRB796 (1M;Kumaetal., 2005) followedbyNMDA(0–50M,10min) and cell deathmeasuredbyLDHassayas in Figure3e (n9).b, Cortical neuron cultureswerepretreatedwithPSD-95-nNOS
interaction inhibitor IC87201 (10M; Florio et al., 2009) as indicated followed by NMDA (0–50M) and cell death measured by LDH assay as in a (n 9). c, d, Cortical neuron cultures were
pretreated with PSD-95-nNOS interaction inhibitor IC87201 (10M) as in b and excitotoxic activation of p38 was induced with NMDA (0 or 50M, 10 min) where indicated. Activation of p38 was
measured by immunoblotting for phospho-p38 and total p38 as loading control (c, representative blots, n 5), showing that the inhibitor partly reduced NMDA-evoked p38 activation (d). e, f,
Cortical neuron cultureswere pretreated 1hwith L-TAT-GESVpeptide (1M, “GESV”) and L-TATwithout GESV (“TAT”) sequence orwithout peptide, followedbyNMDA (50M, 10min) as indicated.
Activation of p38 was measured as in c and d (e, representative blots, n 4), showing the peptide reduced p38 activation after NMDA (f). g, h, The NO donor DeaNONOate bypasses the
NR–PSD-95–nNOS complex to induce p38MAPK (Cao et al., 2005). This activation, shown here in cortical neuron cultures treated for 10min with 100M NO donor DeaNONOate, is not affected by
the neuroprotective cell-permeable version of the ligand of the nNOS core PDZ domain ligand, L-TAT-GESV, added 1 h beforehand at 1M. This is in contrast to its inhibition of excitotoxic activation
of p38MAPK in cortical neurons shown in e and f. Activation of p38MAPK detected by blotting with phospho-p38 antibody (g, top) and with p38 antibody as a loading control (g, bottom). h,
Quantitated data (means SEM, n 4) is shown and analyzed by ANOVA. i, j, The same experimentswere performed using IC87201 (10M) instead of peptide, as shown (means SEM, n 3).
IC87201 did not prevent NO donor-evoked increases in phospho-p38. *p 0.05, **p 0.01, and ***p 0.001, respectively, by Bonferroni post hoc test after ANOVA in all cases.
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the recruitment of NOS1AP to nNOS prevents both p38MAPK
activation and cell death induced by NMDA but not NO donor.
The recruitment of the MKK3-binding protein NOS1AP to
nNOS is therefore likely to be a critical event in excitotoxic sig-
naling. Consistent with a role for MKK3 suggested here, we have
previously demonstrated that dominant-negativeMKK3 reduces
excitotoxic activation of p38MAPK and neuronal death (Cao et
al., 2004). However, dominant-negatives act by interaction with
upstream and downstream targets and therefore are more infor-
mative about the role of the binding partners than MKK3 itself.
Figure 5. Knockdown of NOS1AP reduces excitotoxic death and p38MAPK activation. a, Cortical neuron cultures were transfected with independent nontargeting siRNAs or siRNAs targeting
NOS1AP as indicated. Both siNOS1AP #1 and #2 reduce NOS1AP protein levels detected by immunoblotting by50%,with-actin used as a loading control (n 5). b–d, Cortical neuron cultures
were transfected with siRNAs as in a and excitotoxic stress applied with NMDA (50M, 1 h) as indicated. Cell death was measured after 24 h. b, Cultures were stained with Hoechst 33342/PI as in
Figure 3. Quantification of cell death by PI staining (c) and detection of LDH released into themedium (d) are shown (n 27). Even though siNOS1APs only reduce protein levels 50%, a significant
protection was detected. e–g, Cortical neuron cultures were transfected as in a and b and 10 min after stimulation with NMDA (50 M), cells were lysed and p38 activation was detected by
immunoblotting for phospho-p38, and total p38 as a loading control and NOS1AP to confirm knockdown (e). Quantification of replicates (n 3) are shown for p38 activation (f) and NOS1AP
knockdown (g). These data used set #1 siRNAs. h–j, Similar results as in e–gwere obtainedwith siRNA set #2 (n 3). *p 0.05, **p 0.01, and ***p 0.001, respectively, by Bonferroni post
hoc test after ANOVA in all cases.
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Figure 6. NOS1AP recruits the p38 activator MKK3. a, The endogenous interaction of MKK3with NOS1AP in brain was comparedwith previously reportedMKK3-interacting proteins. MKK3was
immunoprecipitated from lysed cerebral cortex usingMKK3-specific antiserum raised in rabbit, followed by sequestration of immobilized protein A. Immunoprecipitation (Figure legend continues.)
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For this reason we identified an MKK3-targeting siRNA that re-
duces levels of the protein by half and found that it also reduced
excitotoxic p38MAPK activation by50% (Fig. 6d–f). This sup-
ports the inferred role for MKK3 in excitotoxicity and suggests a
lack of compensation by other MKKs in this system.
However, this does not explain the NMDA-evoked recruit-
ment of NOS1AP to nNOS that we observed (Fig. 3). We asked
whetherNMDA-evoked activation of nNOSmight be involved in
the response, by repeating the coimmunoprecipitation experi-
ment in reduced arginine in the absence or presence of inhibitors
of NOS or nNOS. This revealed that the three different inhibitors
of NOS tested significantly reduced the interaction (Fig. 6g,h).
Furthermore, binding proteins forMAP3Ks that can be activated
by NO, such as PSD-95 and DAB2IP/AIP, are detected in NR
associated fractions, even after stringent washing (Savinainen et
al., 2001; Yoshimura et al., 2004; Zhang et al., 2004; Follstaedt et
al., 2008; Hu et al., 2012). In contrast, p38MAPK appears to be a
highly mobile molecule without long-lasting interactions; we
find its gel filtration elution profile in brain extracts is consistent
with a monomer and we did not detect coimmunoprecipitation
even with MKK3 (our unpublished data) though it clearly inter-
acts long enough to act as a substrate. Therefore regulation of
MKK3 availability could be a critical determinant of the ability of
NRs to activate p38MAPK. Our data presented here suggest that
the nNOS-evoked recruitment of MKK3-binding protein
NOS1AP to nNOS (Fig. 6i) may be a rate-limiting step in excito-
toxicity and could become an attractive candidate for therapeutic
approaches.
TAT-GESV enters neurons in vivo and doubles surviving
tissue in neonatal hypoxia-ischemia
Based on these encouraging results, we evaluated the possible use
of the TAT-GESV peptide in an animal model of perinatal as-
phyxia, an excitotoxic condition and major cause of perinatal
death and neurological disability for which no pharmacological
treatments are available in humans. The severe Rice–Vannucci
model of neonatal hypoxia-ischemia (Rice et al., 1981) is com-
monly accepted as one of the most clinically relevant models for
this condition. The model combines ligation of the right carotid
artery with exposure to hypoxia in 7-d-old rats, and produces a
substantial and highly reproducible lesion. We previously dem-
onstrated that this rat model exhibited no protection with
D-JNKI (Ginet et al., 2009), but pretreatments with inhibitors of
nNOS (Hamada et al., 1994; Ishida et al., 2001) and p38MAPK
(Hee Han et al., 2002) were shown to be neuroprotective. This
model therefore appeared suitable for evaluation with
TAT-GESV.
First we characterized a negative control L-TAT peptide, eval-
uated in Figure 3, g and i, corresponding to the nonbinding mu-
tant peptide “GASA” shown in Figure 1b, in which the critical
C-terminal andC-2 position amino acids are replaced by alanine.
We immobilized peptides on beads and pulled down recombi-
nant proteins. We found that L-TAT-GESV selectively pulled
down GST-nNOS1–99 (not GST) and mutant peptide L-TAT-
GASA failed to pull down any protein tested (Fig. 7a).
For in vivo experimentswe decided to useD-form amino acids
in inverse sequence in place of L-form for the TAT sequence, i.e.,
“retroinverso-form” TAT, to promote long-term stability of the
peptide (Borsello et al., 2003). The free COOH of the terminal
valine was essential for activity (Fig. 3g) as expected for a PDZ
interacting peptide (Harris et al., 2001). Therefore the ligand
sequence cannot be reversed and we kept this part of the peptide
in L-form. First we evaluated neuroprotection in cultures using
assays as in Figure 3, based on PI (Fig. 7b) and LDH (data not
shown). This demonstrated that D-TAT fused GESV nonamer
also protected against excitotoxicity in cortical cultures.
Subsequently we tested the ability of intracerebroventricularly
delivered D-TAT-GESV peptide to enter neurons in the brain.
Based on pilot experiments with 10, 100, and 1000 ng, we used
100 ng in all in vivo studies shown. The intracerebroventricularly
mode of delivery did not lead us to expect uniform distribution
throughout the body, which would have resulted in only3 nM
concentration (Mr 2375). It is difficult to precisely predict the
concentration of peptide in the brain, but in studies using the
50% larger D-JNKI peptide, 1–2 M, is typically used in cultures
while in vivo even 16 ng is effective intracerebroventricularly
(Borsello et al., 2003;Hirt et al., 2004). This suggests that substan-
tially less peptide is required intracerebroventricularly for effect
than would be expected from assuming complete dispersion
throughout the body. Six hours after intracerebroventricular in-
jection and hypoxia-ischemia, a dansylated form of TAT-GESV
was detected in neurons, identified by NeuN staining, in both
striatum (Fig. 7c) and cortex (Fig. 7d) but not astrocytes, identi-
fied by GFAP staining. The selective uptake by neurons is ex-
pected as it has previously been shownusing fluorescently labeled
TAT peptides that selective endocytosis into neurons is stimu-
lated by excitotoxic conditions (Vaslin et al., 2009).
We found that hypoxia-ischemia causes activation of
p38MAPK peaking at 30min (Fig. 7e), consistent with the results
4
(Figure legend continued.) of MKK3was detected by immunoblotting as was coimmunopre-
cipitation ofNOS1APanda very slight coimmunoprecipitation of thepreviously describedMKK3
binding protein PKN (Takahashi et al., 2003). Input (1.5% of total) and immunoprecipitate
(12.5%) were loaded. Pre-immune serum from the same rabbit was used as negative control
(representative blots, n 3). b, Interaction of NOS1AP with MKK3 was compared with a pre-
viously described NOS1AP-interacting protein, DexRas (Fang et al., 2000). HEK-293 cells were
transfected with VenusYFP vector or Venus fused to NOS1AP N terminus together with
luciferase-taggedDexRas,MKK3, or the empty luciferase tag vector as indicated. Venusproteins
were immunoprecipitated from cell lysates with immobilized GFP-binding protein (recombi-
nant single-chain camelid antibody), and interaction quantified by precipitated luciferase sig-
nal normalized to the corresponding lysate luciferase signal, showing negligible interaction
with negative controls and similar interaction of NOS1AP with DexRas or MKK3 (n 3). c,
Interaction of MKK3with NOS1APwas compared with the previously describedMKK3 interact-
ing protein ASK1. Immobilized recombinant GST-fused MKK3 (2g) and GST as control were
used to precipitate luciferase-tagged NOS1AP and ASK1 proteins from transfected HEK-293 cell
lysates. Interaction was quantified and normalized as in b, indicating negligible interaction
with negative controls and similar interaction of GST-MKK3with ASK1 or NOS1AP (n 3).d–f,
Cortical neuron cultures were transfected with nontargeting siRNA or siRNA targetingMKK3 as
indicated. 10min after stimulationwithNMDA (50M), cellswere lysed andp38activationwas
detectedby immunoblotting for phospho-p38, total p38 as a loading control, andMKK3protein
level to confirm knockdown with -actin used as a loading control (n  3). g, h, Cortical
neurons were treated for 1 h in arginine-free medium with or without NOS inhibitors 7-NI,
NpARG, and L-NAME as indicated, followed by 10 min with or without 50 M NMDA. Cells
were lysed and immunoprecipitatedwith anti-nNOS followedby immobilized protein A. Copre-
cipitated NOS1AP, precipitated nNOS, and input samples were measured by immunoblotting.
Representative blots (n 4) are shown, indicating the coprecipitation of NOS1AP with nNOS
was reduced by each NOS inhibitor. i, Schematic representation of the proposed role of NOS1AP
in excitotoxic activation of p38MAPK downstream of the NR–PSD-95–nNOS ternary complex.
The latter complex is known to mediate excitotoxic death via p38MAPK (Cao et al., 2005; So-
riano et al., 2008), and be colocalized with binding proteins for NO-activated MAP3Ks (Savi-
nainen et al., 2001; Yoshimura et al., 2004; Zhang et al., 2004; Follstaedt et al., 2008; Hu et al.,
2012). We find that NMDA induces recruitment by nNOS of theMKK3-binding protein NOS1AP,
which is a critical step in the signaling pathway. The use of catalytic inhibitors of NOS suggests
that the recruitment is also dependent on NO. Thus both p38 activation and neuronal death are
reduced both by competition with the NOS1AP-nNOS interaction and by siRNAs targeting
NOS1AP. *p 0.05, **p 0.01, and ***p 0.001, respectively, by Bonferroni post hoc test
after ANOVA in all cases.
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of Hee Han et al. (2002), and injection with D-TAT-GESV sig-
nificantly reduced the hypoxia–ischemia-induced phospho-
p38MAPK level compared with control peptide-treated animals,
30 min after hypoxia-ischemia (Fig. 7f–g). The amount of re-
maining unlesioned tissue in control peptide-treated animals
24 h after insult (Fig. 8a) was very similar to our previous obser-
vations using independent negative controls (Ginet et al., 2009).
D-TAT-GESV significantly increased undamaged tissue, deter-
mined by microscopic examination, compared with control (D-
TAT-GASA-treated animals) 24 h after hypoxia-ischemia (Fig.
8a,b). The neuroprotective effect of D-TAT-GESV was main-
tained 1 week after the insult with a doubling of surviving tissue
(Fig. 8c,d). This amounts to20% increase in intact tissue, which
is the same percentage increase we observed with the p38MAPK
inhibitor SB203580 (Fig. 8e; note theDMSOcarrier for SB203580
influences the baseline lesion, see Materials and Methods). This
confirms that D-TAT-GESV is as neuroprotective as a small mol-
ecule p38MAPK inhibitor in vivo, though the immediate target of
D-TAT-GESV (class III PDZ) is very different.
Discussion
Our results identify a new pathway mediating excitotoxicity
downstream of nNOS. Excitotoxicity is a calcium-dependent
mechanism of neurodegeneration common to a range of condi-
tions for which there are few or no effective treatments. Unfor-
tunately, targeting calcium influx has not been a useful
therapeutic approach, whereas subsequent neurodegenerative
events amenable to therapeutic intervention have remained elu-
sive. The NR–PSD-95–nNOS complex and stress-activated
MAPKs are implicated in excitotoxicity, hence promising recent
clinical trials for cerebral ischemia with TAT-NR2B9C, the pep-
tidic drug targeting PSD-95 (Aarts et al., 2002; Hill et al., 2012)
and similar plans for an inhibitor of JNK (Borsello et al., 2003).
However, it is well established that these proteins are major reg-
ulatory hubs determining neuronal function (Coffey et al., 2002;
Kim and Sheng, 2004; Bjo¨rkblom et al., 2005; Westerlund et al.,
2008, 2011). For example, knockdown of PSD-95 alone elimi-
nates 50% of synaptic AMPA receptors and AMPA current of
Figure 7. TAT-GESV enters neurons in the brain and reduces p38 activation after hypoxia-ischemia. a, The ability of TAT-fused GESV peptide to interact with nNOS core PDZ domain and loss of
binding in the ala-mutant peptide “TAT-GASA” was evaluated by immobilization of corresponding peptides on reactive beads as in Figure 2e, using inactivated beads as negative control (“no
peptide”), followed by pulldown of soluble GST-fused nNOS1–99 or GST as negative control. Pulldown was compared with protein levels in input by immunoblotting (n 3). b, Cortical neurons
were treated 1 h with or without D-TAT-GASA or D-TAT-GESV (1M), and excitotoxicity induced by 1 h stimulation with 25 or 50M NMDA as in Figure 3. The percentage of PI-positive cells were
shown (means SEM, n 8, *p 0.05 and **p 0.01, respectively, by Bonferroni post hoc test after ANOVA. c, d, Penetration of D-TAT-GESV into cells in a neonatal hypoxia-ischemia model
was evaluated. Dansyl-labeled D-TAT GESV (10 g) was injected intracerebroventricularly in 7-d-old rats just after common carotid ligation. Brains were analyzed 6 h after hypoxia-ischemia.
Dansyl-labeled D-TAT-GESVwas detectedwith anti-dansyl antibody and Alexa 488 secondary. Confocal images of double immunolabelingwith NeuNdemonstrate that D-TAT GESV targets neurons
and not GFAP-positive glial cells as shown here for the striatum (c) and the cortex (d). Scale bar 50 m. e, Neonatal hypoxia-ischemia induces a rapid and transient activation of p38.
Quantification of the level of phospho-p38 in striatal protein extracts shows an increase at 30 min to 3 h after hypoxia-ischemia. Data (mean SEM, n 5–6) were analyzed by Welch’s ANOVA
followed by post hoc Tukey–Kramer test; *p 0.05 and **p 0.01, respectively. f, g, Intracerebroventricular injection of D-TAT-GESV (100 ng) significantly decreased the level of phosphorylated
p38 in the striatum30minafter hypoxia-ischemia comparedwithD-TATGASA-treated rat striatum. Immunoblots in fwerequantified for level of phospho-p38andp38 (g). Data (mean SEM,n
4–8) were analyzed by Welch’s ANOVA followed by a post hoc Tukey–Kramer test. *p 0.05.
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EPSCs, while the knock-out mouse escapes this deficit as the
developmental MAGUK, SAP102, remains at the synapse into
adulthood because it cannot be replaced by the lacking PSD-95
molecules (Elias et al., 2006; for review, see Elias and Nicoll,
2007). Peptide-based blockade of the PDZ domains of PSD-95
might have less effect than knockdown, and the recent TAT-
NR2B9C clinical trial suggests it is well tolerated when delivered
as a single dose (Hill et al., 2012). However, PSD-95 is thought to
act on AMPA receptor function via those PDZ domains (Elias
andNicoll, 2007) targeted by TAT-NR2B9C, and this peptide has
been reported to impact on synaptic plasticity (Gardoni et al.,
2009). Therefore targets with greater functional specificity must
be identified. For this reason we sought potential targets down-
stream of PSD-95. We focused on the p38 pathway, which is well
known to contribute to excitotoxicity tomitigate the risk of iden-
tifying pathways not related to cell death.
The data presented here reveal the requirement of NOS1AP
for excitotoxic signaling, p38MAPK activation, downstream of
theNR–PSD-95–nNOS complex. Furthermore they demonstrate
that NOS1AP interacts with MKK3, the kinase required for exci-
totoxic activation of p38, which is also required for the pathway;
that excitotoxicity induces recruitment of NOS1AP to nNOS;
and that competing for the interaction of nNOS with NOS1AP
reduces excitotoxic signaling. In addition, we found that the
NMDA-evoked recruitment ofNOS1AP to nNOSwas dependent
not only on nNOS protein but also on catalytic activity as it was
reduced by three different catalytic inhibitors of NOS (Fig. 6g,h).
It is not clear exactly how this catalytic activity leads to the in-
creased binding, as NO has numerous targets. Nevertheless this
study supports a cell-autonomous role for nNOS, in concert with
its interacting proteins (Fig. 6i), in the excitotoxic death of a
substantial portion of neurons. This may appear to be at odds
with the proposal that1% of neurons that exhibit high levels of
nNOS (Bredt et al., 1991), so-called “nNOS neurons,” are re-
sponsible for excitotoxic death of neighboring neurons (Samdani
et al., 1997). However, these authors acknowledged this does not
mean the remaining neurons contain no nNOS at all (Weiss et al.,
1998); on the contrary low-level expression may be widespread
and fixation conditions greatly influence the detection of lower
levels of nNOS (Wendland et al., 1994; Burette et al., 2002; Lang-
naese et al., 2007). Langnaese et al. (2007) has argued that the
generally accepted synaptic roles for nNOS suggest that the ap-
parently minimal and even undetectable levels of nNOS in the
neuropil may be functionally more significant than staining
might suggest; the same may well be true for nNOS in excitotox-
icity. In our cultures we observe not only the few intensely but
diffusely stained neurons but also a lower level of punctate stain-
ing that is widely distributed among the remaining neurons (Fig.
2b). Our data suggest it is not bulk-free cytoplasmic nNOS but
only the nNOS molecules associating with appropriate partners
that can initiate excitotoxic signaling cascades (Fig. 6i), hence the
neuroprotection achieved by disrupting protein interactions.
There is a large mismatch between the high concentrations of
exogenously administered NO required to cause neurodegenera-
tion and the amounts estimated to be generated under excito-
toxic conditions (discussed in Keynes et al., 2004). One
explanation might be that during excitotoxic stimulation the
concentration of NO in the immediate vicinity of active nNOS is
sufficient tomediate excitotoxic signaling without substantial in-
crease in bulk NO levels as results from use of exogenous donors.
Indeed, submicrometer NO gradients are predicted in neurons,
resulting from both NO-inactivation mechanisms (Keynes et al.,
2004) and the known rapid diffusion of local NO generated from
spatially constrained sources, i.e., nNOS (Philippides et al.,
2005). Themajorweakness with this hypothesis had been the lack
of evidence for excitotoxic effector pathways either localized to or
requiring physical association with nNOS. The recruitment of
MKK3-interacting protein NOS1AP to nNOS reported here may
represent such a pathway.
Based on our findings we designed a peptidic drug-like mol-
ecule that limits excitotoxic signaling and damage not only in cell
culture, but also in an animal model of perinatal asphyxia in
which, notably, the peptidic JNK inhibitor D-JNKI is completely
ineffective (Ginet et al., 2009). While these results suggest we
found a novel targetable step in excitotoxic signaling, substan-
tially more in vivo work remains to determine whether the pep-
tide we designed or future derivativesmight have any therapeutic
value. One must remain cautious as 1000 experimental treat-
ments based on cellular and rodent studies have failed to translate
to clinical value in humans (Hill et al., 2012). The multiple pos-
Figure 8. TAT-GESV doubles surviving tissue 1 and 7 d after neonatal hypoxia-ischemia. a–d, Administration of 100 ng of D-TAT-GESV intracerebroventricularly just after carotid occlusion
doubles the volumeof intact tissue in the lesioned hemisphere comparison to injection of the negative control peptide.a, Representative Nissl-stained coronal sections of neonatal rat brain (7 d old)
at the level of the striatum and hippocampus 24 h after hypoxia-ischemia and injection with 100 ng of negative peptide D-TAT-GASA or with D-TAT-GESV as shown. Dotted black lines indicate the
intact tissue in the lesioned hemisphere determined bymicroscopic examination. Scale bar, 1mm. b, Mean lesion size SEM is shown as a histogramwith individual data points superposed (n
10 and 11 for D-TAT-GASA and D-TAT-GESV-treated animals, respectively), and analyzed by Welch’s ANOVA (one-way ANOVA with unequal variances) followed by a post hoc Tukey–Kramer test.
*p 0.05. c, Representative Nissl-stained coronal sections of neonatal rat brain as in a one week after hypoxia-ischemia and injection with peptides as indicated. Dotted black lines indicate the
intact tissue in the lesioned hemisphere. Scale bar, 1 mm. D-TAT-GESV doubles the level of intact tissue measured 7 d after neonatal hypoxia-ischemia. Means SEMs (n 7) of lesions from
experiments are shown in d, analyzed and graphed as in b, and analyzed byWelch’s ANOVA followed by a post hoc Tukey–Kramer test. *p 0.05. D-TAT-GESV significantly increased the amount
of intact tissue, by 17% comparedwith the D-TAT-GASA control. e, Pretreatmentwith p38MAPK inhibitor SB203580 in DMSO significantly increased the amount of intact tissue ( p 0.05), by 16%
compared with the DMSO carrier control, supporting previous reports of p38MAPK as a determinant of the lesion size in this model (Hee-Han et al., 2002). Mean lesion size SEM is shown as a
histogramwith individual data points superposed (n 6 and 8 for DMSO and SB203580, respectively), and analyzed by Welch’s ANOVA followed by a post hoc Tukey–Kramer test. *p 0.05.
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sible reasons for these failures have been discussed in detail pre-
viously. Nevertheless it is most encouraging that the recent
clinical trial using a peptide targeting PSD-95-PDZ domains,
which are one step upstream of the nNOS3 p38MAPK pathway
we describe here, is the first human trial to suggest that neuro-
protection is possible in ischemic stroke in humans (Hill et al.,
2012) and is not “just a fantasy invented by basic scientists” as
previously proposed (Gladstone et al., 2002).
Specifically, our findings suggest that the interaction between
the core nNOS-PDZ domain and NOS1AP mediates the recruit-
ment of and the requirement for NOS1AP in p38MAPK-
dependent excitotoxic neuronal death. NOS1AP is an adaptor
protein known to bind nNOS but without known enzymatic
function itself and cannot alone explain p38MAPK activation.
However, we demonstrated the existence in brain of complexes
containing NOS1AP and p38-activating MKK, suggesting
NOS1AP might be a novel signaling scaffold capable of integrat-
ing upstream activators (in this case a source of soluble second
messengers, nNOS) with MAPK family members (MKK3 in this
case). Consistent with behavior as a scaffold protein (Dickens et
al., 1997), we find that overexpression of NOS1AP suppresses
nNOS-induced MKK3 activation in a heterologous system (our
unpublished data). Given the abundance of proteins known to
bindNO-activatedMAP3K species of the ASK andMLK families,
such as PSD-95 andDAB2IP, in the vicinity ofNRs (Savinainen et
al., 2001; Yoshimura et al., 2004; Zhang et al., 2004; Follstaedt et
al., 2008; Hu et al., 2012), the supply of MKK is likely to be
limiting. This could therefore explain the requirement for
NOS1AP to scaffold the signaling pathway nearby NR complexes
(Fig. 6i).
We previously reported that the small GTPase Rho also con-
tributes to excitotoxic p38MAPK activation and neuronal death
(Semenova et al., 2007). It remains unclear at present whether
Rho and nNOS pathways contribute independently to the exci-
totoxic p38MAPK pathway or whether these pathways interact.
In no case have we completely eliminated p38MAPK activation
by inhibition of Rho (Semenova et al., 2007), PSD-95-nNOS in-
teraction (Cao et al., 2005), or the nNOS-NOS1AP pathway de-
scribed here, so it is possible these pathways act independently.
Further investigation would be required to determine whether
these two pathways interact upstream of p38 or are truly inde-
pendent of one another.
In summary, our data reveal a previously unrecognized role
for NOS1AP as amediator of p38MAPK activation, an effector of
excitotoxicity downstream of the NR–PSD-95–nNOS ternary
complex (Cao et al., 2005; Soriano et al., 2008). Interestingly the
nNOS-PDZ interacts with highly unusual ligand sequences dis-
tinct from common PDZ binding motifs (Stricker et al., 1997;
Schepens et al., 1997). This may greatly facilitate generation of
selective inhibitor molecules. Furthermore, nNOS-PDZ and
NOS1AP are not known to have major critical functions in neu-
ronal physiology, unlike PSD-95 and JNK (Coffey et al., 2002;
Kim and Sheng, 2004; Bjo¨rkblom et al., 2005; Westerlund et al.,
2008, 2011; Yang et al., 2011), which are currently targeted in
stroke trials. In summary our results, together with the reported
disease associations with the nos1ap gene (Arking et al., 2006;
Becker et al., 2008; Brzustowicz, 2008; Lehtinen et al., 2008),
suggest NOS1APmay be an important new target for drug devel-
opment. Given the historical failure of functionally nonselective
drugs when evaluated for excitotoxic conditions, and the new
promise of protein interaction inhibitors (Hill et al., 2012), we
suggest this unusual protein interaction motif we reveal to be
involved may provide fruitful leads for future development of
drugs targeting excitotoxicity.
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